Last reviewed · How we verify
Pyrimethamine plus Sulfadiazine plus leucoverin
Pyrimethamine plus Sulfadiazine plus leucoverin is a Antiparasitic/antimicrobial combination Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand. It is currently FDA-approved for Toxoplasmosis (particularly CNS toxoplasmosis in immunocompromised patients), Malaria (chloroquine-resistant strains).
This combination inhibits parasitic dihydrofolate reductase to block nucleotide synthesis, with sulfadiazine providing synergistic antimicrobial activity and leucovorin protecting host cells from folate antagonism.
This combination inhibits parasitic dihydrofolate reductase to block nucleotide synthesis, with sulfadiazine providing synergistic antimicrobial activity and leucovorin protecting host cells from folate antagonism. Used for Toxoplasmosis (particularly CNS toxoplasmosis in immunocompromised patients), Malaria (chloroquine-resistant strains).
At a glance
| Generic name | Pyrimethamine plus Sulfadiazine plus leucoverin |
|---|---|
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Drug class | Antiparasitic/antimicrobial combination |
| Target | Dihydrofolate reductase (parasitic and bacterial) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Pyrimethamine is a dihydrofolate reductase inhibitor that disrupts nucleotide synthesis in parasites and certain bacteria. Sulfadiazine inhibits bacterial folate synthesis through a complementary mechanism. Leucovorin (folinic acid) is a reduced folate cofactor that rescues host cell folate metabolism, reducing toxicity while preserving the antimicrobial effect against organisms that cannot utilize exogenous folinic acid.
Approved indications
- Toxoplasmosis (particularly CNS toxoplasmosis in immunocompromised patients)
- Malaria (chloroquine-resistant strains)
Common side effects
- Bone marrow suppression
- Rash
- Gastrointestinal disturbance
- Folate deficiency
- Hepatotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pyrimethamine plus Sulfadiazine plus leucoverin CI brief — competitive landscape report
- Pyrimethamine plus Sulfadiazine plus leucoverin updates RSS · CI watch RSS
- Department of Medical Services Ministry of Public Health of Thailand portfolio CI
Frequently asked questions about Pyrimethamine plus Sulfadiazine plus leucoverin
What is Pyrimethamine plus Sulfadiazine plus leucoverin?
How does Pyrimethamine plus Sulfadiazine plus leucoverin work?
What is Pyrimethamine plus Sulfadiazine plus leucoverin used for?
Who makes Pyrimethamine plus Sulfadiazine plus leucoverin?
What drug class is Pyrimethamine plus Sulfadiazine plus leucoverin in?
What development phase is Pyrimethamine plus Sulfadiazine plus leucoverin in?
What are the side effects of Pyrimethamine plus Sulfadiazine plus leucoverin?
What does Pyrimethamine plus Sulfadiazine plus leucoverin target?
Related
- Drug class: All Antiparasitic/antimicrobial combination drugs
- Target: All drugs targeting Dihydrofolate reductase (parasitic and bacterial)
- Manufacturer: Department of Medical Services Ministry of Public Health of Thailand — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Toxoplasmosis (particularly CNS toxoplasmosis in immunocompromised patients)
- Indication: Drugs for Malaria (chloroquine-resistant strains)
- Compare: Pyrimethamine plus Sulfadiazine plus leucoverin vs similar drugs
- Pricing: Pyrimethamine plus Sulfadiazine plus leucoverin cost, discount & access